NDC Code(s) : 42291-601-01, 42291-602-01, 42291-603-01, 42291-604-01
Packager : AvKARE, Inc.
Category : HUMAN PRESCRIPTION DRUG LABEL
DEA Schedule : CII
Marketing Status : New Drug Application
INGREDIENTS AND APPEARANCE
| Methylphenidate Hydrochloride Methylphenidate Hydrochloride TABLET, EXTENDED RELEASE | ||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
| Methylphenidate Hydrochloride Methylphenidate Hydrochloride TABLET, EXTENDED RELEASE | ||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
| Methylphenidate Hydrochloride Methylphenidate Hydrochloride TABLET, EXTENDED RELEASE | ||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
| Methylphenidate Hydrochloride Methylphenidate Hydrochloride TABLET, EXTENDED RELEASE | ||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
PRINCIPAL DISPLAY PANEL
AvKARE
NDC 42291-601-01
Methylphenidate HCl Extended-Release Tablets, USP
CII
18 mg
100 Tablets Rx Only
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Each tablet contains 18 mg methylphenidate hydrochloride in a controlled-release formulation.
Usual Dosage: Once daily.
See package insert for dosage information.
Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]. Protect from humidity.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
L4229160101 AV Rev. 06/15 (P)
N3 42291 60101 7
AvKARE
NDC 42291-602-01
Methylphenidate HCl Extended-Release Tablets, USP
CII
27 mg
100 Tablets Rx Only
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Each tablet contains 27 mg methylphenidate hydrochloride in a controlled-release formulation.
Usual Dosage: Once daily.
See package insert for dosage information.
Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]. Protect from humidity.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
L4229160201 AV Rev. 06/15 (P)
N3 42291 60201 4
AvKARE
NDC 42291-603-01
Methylphenidate HCl Extended-Release Tablets, USP
CII
36 mg
100 Tablets Rx Only
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Each tablet contains 36 mg methylphenidate hydrochloride in a controlled-release formulation.
Usual Dosage: Once daily.
See package insert for dosage information.
Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]. Protect from humidity.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
L4229160301 AV Rev. 06/15 (P)
N3 42291 60301 1
AvKARE
NDC 42291-604-01
Methylphenidate HCl Extended-Release Tablets, USP
CII
54 mg
100 Tablets Rx Only
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Each tablet contains 54 mg methylphenidate hydrochloride in a controlled-release formulation.
Usual Dosage: Once daily.
See package insert for dosage information.
Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]. Protect from humidity.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
L4229160401 AV Rev. 06/15 (P)
N3 42291 60401 8
